Combination regimens that pair BCL-2 blockade with proteasome, histone deacetylase, or antiretroviral therapies show synergistic effects, enhancing cytotoxicity and overcoming resistance mechanisms characteristic of ATLL. Here, BCL2 is linked to adult T-cell leukemia/lymphoma.